E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers C > Headlines for Celldex Therapeutics Inc. > News item
Published on 2/4/2013 in the Prospect News PIPE Daily.

Celldex plans to sell $75 million of common stock in public offering

Jefferies and Leerink Swann are joint bookrunning managers

By Susanna Moon

Chicago, Feb. 4 - Celldex Therapeutics, Inc. plans to sell $75 million of its common stock in a public offering with Jefferies & Co., Inc. and Leerink Swann LLC as the joint bookrunning managers and underwriters.

The company's stock (Nasdaq: CLDX) closed at $7.56 on Feb. 1.

Celldex is a biotechnology company based in Needham, Mass.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.